Feasibility and Safety of High‐Dose Proton Re‐Irradiation in Recurrent Pediatric Central Nervous System Tumors: A Single‐Institution Retrospective Study

Pediatric Blood & Cancer 2026 Open access

Read full text
Authors: Jin‐Ho Song, Jonathan Baron, Carlos Chavez Perez, Sidharth Ramesh, Jane Minturn, Kavita A. Desai, Amish C. Shah, Jean M. Belasco, Kristina A. Cole, Michael J. Fisher, Phillip B. Storm, Peter M. Madsen
+4 more Goldie Kurtz, Robert A. Lustig, Christine Hill‐Kayser, Michael J. LaRiviere
DOI: 10.1002/1545-5017.70371
Cited by: 1
References: 18

Abstract

ABSTRACT Purpose Pediatric central nervous system (CNS) tumors often recur despite multimodality therapy. Although re‐irradiation (re‐RT) has historically been limited by concerns for severe late toxicities, modern techniques have renewed interest in this approach. Proton therapy provides dosimetric advantages that may enable curative re‐treatment with reduced normal tissue exposure. Methods We retrospectively reviewed 54 pediatric patients who underwent proton re‐RT for recurrent CNS tumors at our institution (2010–2024). Eligible patients had received prior CNS‐directed RT at ≤20 years of age. Toxicities were graded per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 as acute (

Fields of Study & Subjects

Radiation Therapy and Dosimetry Glioma Diagnosis and Treatment Meningioma and schwannoma management

Publication details

Journal / source
Pediatric Blood & Cancer
Publisher
Wiley
Volume
73
Issue
7
Pages
e70371–e70371
Publication date
4 May 2026
Language
EN